

CORRECTION

Open Access



# Correction to: The value of co-creating a clinical outcome assessment strategy for clinical trial research: process and lessons learnt

Thomas Morel<sup>1\*</sup>, Karlin Schroeder<sup>2</sup>, Sophie Cleanthous<sup>3</sup>, John Andrejack<sup>4</sup>, Geraldine Blavat<sup>4</sup>, William Brooks<sup>4</sup>, Lesley Gosden<sup>5</sup>, Carroll Siu<sup>5</sup>, Natasha Ratcliffe<sup>5</sup> and Ashley F. Slagle<sup>6</sup>

**Correction to:**  
**Research Involvement and Engagement (2023) 9:98**  
<https://doi.org/10.1186/s40900-023-00505-7>

Following publication of the original article [1], the authors reported errors in reference 13. The revised link in reference 13 has been indicated hereafter.

The incorrect reference 13 reads:

13. FDA. Assessment of the use of patient experience data in regulatory decision-making final report. <https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical>. Accessed 06 Mar 2023.

The correct reference 13 should read:

13. FDA. Assessment of the use of patient experience data in regulatory decision-making final report. <https://www.fda.gov/drugs/development-approval-process-drugs/assessment-use-patient-experience-data-regulatory-decision-making> Accessed 06 Mar 2023.

All the changes requested are implemented in this correction and the original article [1] has been corrected.

Published online: 09 January 2024

## Reference

1. Morel T, Schroeder K, Cleanthous S, et al. The value of co-creating a clinical outcome assessment strategy for clinical trial research: process and lessons learnt. *Res Involv Engagem*. 2023;9:98. <https://doi.org/10.1186/s40900-023-00505-7>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1186/s40900-023-00505-7>.

\*Correspondence:

Thomas Morel  
[thomas.morel@ucb.com](mailto:thomas.morel@ucb.com)

<sup>1</sup> Patient-Centred Outcomes Research, UCB Pharma, Allée de La Recherche 60, 1070 Anderlecht, Brussels, Belgium

<sup>2</sup> Parkinson's Foundation, New York, NY, USA

<sup>3</sup> Modus Outcomes, a Division of Thread, London, UK

<sup>4</sup> Parkinson's Foundation, New York, NY, USA

<sup>5</sup> Parkinson's UK, London, UK

<sup>6</sup> Aspen Consulting, LLC, Steamboat Springs, CO, USA



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.